Massachusetts General Hospital and Brigham and Women’s Hospital have chosen to adopt this new technology.
Mass General and Brigham and Women’s Adopt New Technology
MOUNTAIN VIEW, Calif., Nov. 6, 2017 /PRNewswire/ -- Omnicell (NASDAQ: OMCL), a leading provider of medication management and supply chain solutions to health systems, today announced the launch of IVX Workflow, an innovative sterile compounding workflow solution that leverages integrated barcode scanning, gravimetric or volumetric verification, advanced image recognition, photo documentation and label printing as part of a compact all-in-one package designed for safe, accurate, and streamlined IV sterile compounding. Massachusetts General Hospital and Brigham and Women’s Hospital have chosen to adopt this new technology.
Omnicell® IVX Workflow is an all-in-one device designed for easy placement within laminar airflow (LAF) hoods or isolators. It supports best practices in aseptic technique by providing step-by-step instructions to guide technicians in preparing IV doses according to set protocols—safely, accurately, and repeatedly.
IVX Workflow is powered by Omnicell® IVX Cloud, a fully web-based software suite designed to manage all aspects of IV compounding workflow operation across a hospital or health system. IVX Cloud enables management of orders throughout the IV compounding process, with capabilities including:
- Comprehensive formulary management, including access to Omnicell’s cloud-based formulary database for specific gravity data, cGMP beyond use dating (BUD) studies, and consumable configuration
- Flexible workflow design to create risk-based workflows
- Remote pharmacist checking
- Robust reporting and analytics to drive optimization and efficiency
- Integration with pharmacy and hospital information systems
IVX Cloud will also be integrated with Simplifi 797®, providing hospital pharmacies with a comprehensive solution to address safety, quality and compliance across compounding operations. A turnkey quality management solution from Wolters Kluwer, Simplifi 797 simplifies, streamlines, and automates USP < 797 > and USP < 800 > compliance processes and cleanroom operations, enabling a measurable reduction in resources required to comply with USP standards. It leverages expert content to provide best practice tools and resources—risk management and quality assurance practices, comprehensive policies and procedures, staff training and evaluations—to elevate staff competencies and keep staff and patients safe.
“The launch of IVX Workflow and IVX Cloud is another example of Omnicell’s commitment to innovation, developing new technology to address our customers’ most critical challenges,” said Rob Seim, president, Global Automation and Medication Adherence. “We continue to focus on opportunities, across the continuum of care, where we can leverage our broadening portfolio to positively impact the future of healthcare.”
Omnicell will be showcasing the IVX Workflow and IVX Cloud solutions at the American Society of Health-System Pharmacists (ASHP) 52nd Annual Midyear Clinical Meeting & Exhibition in Orlando, December 3 through 7. To learn more, visit
www.omnicell.com/ivxworkflow.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient’s home.
Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.
The Omnicell SureMed® solution provides innovative medication adherence packaging to help reduce costly hospital readmissions. These medication adherence solutions are used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom. These pharmacies are served via Omnicell’s sales channels and our solutions enable them to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
Recent acquisitions, including Ateb, have added distinct capabilities, particularly in central pharmacy, IV robotics and pharmacy software, creating the broadest medication management product portfolio in the industry.
For more information about Omnicell, Inc. please visit www.omnicell.com.
OMCL-G
Editor’s Notes:
- All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company’s external website, omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or registered trademarks of their respective companies.
SOURCE Omnicell, Inc.
